David Mincher

David Mincher

Dr David Mincher

Senior Lecturer

Date


7 results

Design of a New Peptide Substrate Probe of the Putative Biomarker Legumain with Potential Application in Prostate Cancer Diagnosis ex vivo

Journal Article
Mathur, S., Turnbull, A., Akaev, I., Stevens, C., Agrawal, N., Chopra, M., & Mincher, D. (in press)
Design of a New Peptide Substrate Probe of the Putative Biomarker Legumain with Potential Application in Prostate Cancer Diagnosis ex vivo. International Journal of Peptide Research and Therapeutics, https://doi.org/10.1007/s10989-019-09994-1
The lysosomal endoprotease legumain (asparaginyl endoprotease) has been proposed as a putative biomarker in prostate tumours, in which the enzyme is markedly overexpressed. Ov...

Development of mitochondria- and protease-specific prodrugs in the potential treatment of parasitic helminth infections

Presentation / Conference
Oluwadare, E., Rehan, A., Ding, Y., Turnbull, A., Malone, E., Mincher, D., & Proudfoot, L. (2016, September)
Development of mitochondria- and protease-specific prodrugs in the potential treatment of parasitic helminth infections. Poster presented at Molecular & Cellular Biology of Helminth Parasites X, Hydra, Greece
Anthelmintic resistance and the shortage of new drugs represent an urgent need for the development of novel anti-parasite drugs with effective delivery to the target site. Red...

Design and evaluation of novel theranostic fluorogenic dual probe-prodrug in cancer

Journal Article
Mathur, S., Mincher, D., Turnbull, A., Stevens, C., & Poole, A. (2016)
Design and evaluation of novel theranostic fluorogenic dual probe-prodrug in cancer. European Journal of Cancer, 61, S142. https://doi.org/10.1016/s0959-8049%2816%2961501-0
Background: In spite of major advances in the diagnosis and treatment of cancer, there remains a paucity of biomarkers for early detection. Legumain is a potential cancer biom...

Targeting an MMP-9-activated prodrug to multiple myeloma diseased bone marrow: a proof of principle in the 5T33MM mouse model.

Journal Article
Van Valckenborgh, E., Mincher, D., Di Salvo, A., Van Riet, I., Young, L., Van Camp, B. & Vanderkerken, K. (2005)
Targeting an MMP-9-activated prodrug to multiple myeloma diseased bone marrow: a proof of principle in the 5T33MM mouse model. Leukemia. 19, 1628 -1633. doi:10.1038/sj.leu.2403866. ISSN 0887-6924
Multiple myeloma (MM) is an incurable B-cell cancer characterised by the monoclonal proliferation of tumour cells in the bone marrow (BM). It has been described that matrix me...

Oxoazabenzo[de]anthracenes conjugated to Amino Acids: Synthesis and evaluation as DNA-binding antitumor agents.

Journal Article
Dias, N., Goossens, J., Baldeyrou, B., Lansiaux, A., Colson, P., Di Salvo, A., …Bailly, C. (2005)
Oxoazabenzo[de]anthracenes conjugated to Amino Acids: Synthesis and evaluation as DNA-binding antitumor agents. Bioconjugate Chemistry. 16, 949 - 958. doi:10.1021/bc050065x. ISSN 1043-1802
We report the synthesis of an original series of oxoazabenzo[de]anthracenes conjugated to an amino acid: Ala, Phe, Pro, Lys, or Gly (4a-e, respectively). The compounds, derive...

Anthracene derivatives as anti-cancer agents.

Patent
Mincher, D. & Turnbull, A. (2004)
Anthracene derivatives as anti-cancer agents.
The present invention relates to compounds which are based on an anthraquinone nucleus for use in medicine, particularly as anti-cancer agents which exert their effects throug...

Stereospecific synthesis of chiral caprolactone monomers from D-glucose.

Journal Article
Defossemont, G. & Mincher, D. (2003)
Stereospecific synthesis of chiral caprolactone monomers from D-glucose. Carbohydrate Research. 338, 563-565. doi:10.1016/S0008-6215(02)00490-1. ISSN 0008-6215
The synthesis and characterisation of a novel chiral bicyclic oxacaprolactone is reported. The choice of diisopropylidene- -glucose as a starting material allowed selective in...

Current Post Grad projects

Previous Post Grad projects